All In Biotech

Drug Trial Radar · NCT06208748

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST Who Progressed on Sunitinib Monotherapy

Last checked: Nov 20, 2026Latest source record: Oct 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Aug 1, 2024

Primary completion

Jun 2026

Study completion Jun 2027

Sponsor

Lead sponsor
Sarcoma Alliance for Research through CollaborationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cogent Biosciences, Inc.; Dana-Farber Cancer Institute; The Life Raft Group
First posted
Jan 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.

Conditions

  • Gastrointestinal Stromal Tumors
  • GIST

Interventions

  • Bezuclastinib in combination with sunitinibDrug

    Bezuclastinib in combination with sunitinib (sutent)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To estimate the median progression free survival (mPFS)Time frame: From the time of first dose to the occurrence of disease progression (as accessed by mRECIST v1.1) or death due to any cause prior to documented disease progression, up to 2 years..

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Sylvester Comprehensive Cancer Center, University of Miami

    Miami, Florida

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Oregon Health & Science University

    Portland, Oregon

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.